trial

Treatment of Refractory Auditory Verbal Hallucinations With tDCS in Schizophrenia

NCTId NCT02451371
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Completed
Enrollment 10 (actual)
Sponsored by Seoul National University Hospital
Primary completion 2016-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Completed
Enrollment
10 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2016-08
Primary completion
2016-12
Eligibility
ALL · 19 Years · 50 Years

Interventions & indications

Drugs
TDCS

Sponsors

Seoul National University HospitalLead Sponsor

Investigators

1
Jun Soo Kwon, MD, PhDPrincipal Investigator

Sites

1 total
Seoul, South Korea

Linked catalysts

1
Treatment of Refractory Auditory Verbal Hallucinations With tDCS in Schizophreni — primary completion2016-12

Facts & assertions

4 sourced
Enrollment
10
Phase
PHASE1,PHASE2
Primary Completion Date
2016-12
Status
COMPLETED
relationships
The graph out of here
drug
TDCS
drug
lead_sponsor
Seoul National University Hospital
company
indication
Schizophrenia
indication
Hallucinations
indication
Schizophrenia
indication
investigator
Jun Soo Kwon, MD, PhD
person